SC RYBREVANT approved by European Commission for Q3W and Q4W dosing for patients with advanced EGFR-mutated NSCLC
“The approval of these new subcutaneous dosing regimens marks an important step in Johnson & Johnson’s commitment to transforming the treatment journey for patients with EGFR-mutated non-small cell lung cancer,” said Henar Hevia, Ph.D., Senior Director, EMEA Therapeutic Area Head, Oncology, Johnson & Johnson Innovative Medicine. “By offering more flexible and convenient options, we aim to reduce the burden of treatment on patients and their caregivers across all approved indications, while maintaining the well-established efficacy of intravenous amivantamab. This milestone reflects our broader mission to deliver therapies that not only extend and improve lives but also prioritise the experience of those receiving them.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.